Compare WD 40 Company (WDFC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
WD 40 Company vs State Street SPDR S&P Biotech ETF — how do they compare? WD 40 Company trades at $201.36 (market cap $2.73B), while State Street SPDR S&P Biotech ETF trades at $151.86 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.7× WD 40 Company's market cap, and WD 40 Company pays a 2% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold WD 40 Company for 22 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| WDFC | XBI | |
|---|---|---|
Market Cap | $2.73B | $10.11B |
Volume | 130,665 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $264.91 | $169.55 |
52-Week Low | $187.52 | $104.99 |
Typical Hold Time | 22 Days | 37 Days |
Enterprise Value | $2.79B | — |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WD-40 Company (WDFC) trades at $201.50, down 1.31% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with 55.82% gross margins and 13.22% net income margin, though recent earnings showed mixed results with two beats and one miss. Analyst consensus is mixed with 71% hold ratings despite a $475 price target, while institutional buying activity remains active. Recent news highlights strategic growth initiatives including global expansion and new CFO leadership.
The stock presents a cautious outlook with strong profitability offset by premium valuations (P/E 30.64) and technical weakness. Upside potential exists from the significant analyst price target premium, but risks include margin pressure from input costs and execution challenges in international markets. Current levels near support at $198-200 may offer entry points for long-term investors.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
